Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 1, Issue 1
  5. Article
Volume 1, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Immunity-related issues are the main concerns of patients undergoing inflammatory bowel disease (IBD) treatment. The treatment of IBD during the last decade has evolved due to the ever-increasing utilization of immunomodulators, which has caused the potential of contracting opportunistic infections to become the main immunity concern for patients affected by IBD.

Studies on opportunistic infections in patients with IBD identified in databases such as Google Scholar, PubMed, and Scopus were reviewed and included.

IBD patients are a high-risk population for opportunistic infections, with age being a significant factor. The primary therapy for IBD patients includes the suppression of the immunity system, together with immunodeficiency and biological treatments, which, first of all, must be standardized. Since treatment with suppressive medicine, which is the original method for curing IBD, causes viral infections and the growth of various bacteria, factors suppressing the body's immunity system must be temporarily suspended, or the consumption dosage of sensitive antibiotics should be reduced. Biological treatment and anti-integrin antibodies will lead to the danger of being affected by opportunistic infections in patients with IBD.

Worldwide research society must conduct further research into a therapeutic strategy for IBD patients to reduce susceptibility and the risk of opportunistic infection. Information about how these individuals and the medicines they were given reacted to different infections and more detailed clinical observations are required.

© 2022 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/2666290601666220124111511
2022-04-01
2024-11-26

  • From This Site

    /content/journals/ijghd/10.2174/2666290601666220124111511
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FuehnerT. ErnstD. GreerM. GottliebJ. WelteT. Opportunistic infections in the immunocompromised host.ERS Handbook of Respiratory Medicine201940010.1183/9781849840798.008218
     [Google Scholar]
  2. DaveM. PurohitT. RazonableR. LoftusE.V.Jr Opportunistic infections due to inflammatory bowel disease therapy.Inflamm. Bowel Dis.201420119621210.1097/MIB.0b013e3182a827d224051931
     [Google Scholar]
  3. GlassnerK.L. AbrahamB.P. QuigleyE.M.M. The microbiome and inflammatory bowel disease.J. Allergy Clin. Immunol.20201451162710.1016/j.jaci.2019.11.00331910984
     [Google Scholar]
  4. RubinD.C. ShakerA. LevinM.S. Chronic intestinal inflammation: Inflammatory bowel disease and colitis-associated colon cancer.Front. Immunol.2012310710.3389/fimmu.2012.0010722586430
     [Google Scholar]
  5. AlatabS. SepanlouS.G. IkutaK. VahediH. BisignanoC. SafiriS. SadeghiA. NixonM.R. AbdoliA. AbolhassaniH. AlipourV. AlmadiM.A.H. Almasi-HashianiA. AnushiravaniA. ArablooJ. AtiqueS. AwasthiA. BadawiA. BaigA.A.A. BhalaN. BijaniA. BiondiA. BorzìA.M. BurkeK.E. CarvalhoF. DaryaniA. DubeyM. EftekhariA. FernandesE. FernandesJ.C. FischerF. Haj-MirzaianA. Haj-MirzaianA. HasanzadehA. HashemianM. HayS.I. HoangC.L. HousehM. IlesanmiO.S. Jafari BalalamiN. JamesS.L. KengneA.P. MalekzadehM.M. MeratS. MeretojaT.J. MestrovicT. MirrakhimovE.M. MirzaeiH. MohammadK.A. MokdadA.H. MonastaL. NegoiI. NguyenT.H. NguyenC.T. PourshamsA. PoustchiH. RabieeM. RabieeN. RamezanzadehK. RawafD.L. RawafS. RezaeiN. RobinsonS.R. RonfaniL. SaxenaS. SepehrimaneshM. ShaikhM.A. SharafiZ. SharifM. SiabaniS. SimaA.R. SinghJ.A. SoheiliA. SotoudehmaneshR. SuleriaH.A.R. TesfayB.E. TranB. TsoiD. VacanteM. WondmienehA.B. ZarghiA. ZhangZ-J. DiracM. MalekzadehR. NaghaviM. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet Gastroenterol. Hepatol.202051173010.1016/S2468‑1253(19)30333‑431648971
     [Google Scholar]
  6. NgS.C. ShiH.Y. HamidiN. UnderwoodF.E. TangW. BenchimolE.I. PanaccioneR. GhoshS. WuJ.C.Y. ChanF.K.L. SungJ.J.Y. KaplanG.G. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies.Lancet2017390101142769277810.1016/S0140‑6736(17)32448‑029050646
     [Google Scholar]
  7. FranchimontD. VermeireS. El HousniH. PierikM. Van SteenK. GustotT. QuertinmontE. AbramowiczM. Van GossumA. DevièreJ. RutgeertsP. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis.Gut200453798799210.1136/gut.2003.03020515194649
     [Google Scholar]
  8. ImperatoreN. FoggiaM. RispoA. PatturelliM. CalabreseG. TestaA. NardoneO. PellegriniL. GuarinoA.D. RicciolinoS. TosoneG. CastiglioneF. P139 prevalence of infections in patients affected by inflammatory bowel disease treated with anti-TNF-α agents: a single-centre experience.J. Crohn’s Colitis202014Suppl. 1S206S20710.1093/ecco‑jcc/jjz203.268
     [Google Scholar]
  9. DegasperiE. CaprioliF. El SherifO. BackD. ColomboM. AghemoA. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Expert Rev. Gastroenterol. Hepatol.201610121373138310.1080/17474124.2016.124618127718758
     [Google Scholar]
  10. BadiaE. BarrioJ. Fernández-SalazarL. FuentesA. HontoriaG. SiciliaB. P827 prevalence of viral hepatitis in patients with IBD: A multi-centre and population-based study.J. Crohn’s Colitis201812Suppl. 1S53410.1093/ecco‑jcc/jjx180.954
     [Google Scholar]
  11. HeY. XuP. ChenY. YangR. ChenB. ZengZ. ChenM. Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China.Int. J. Clin. Exp. Med.2015858078808526221373
     [Google Scholar]
  12. AndradeP. Santos-AntunesJ. RodriguesS. LopesS. MacedoG. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.J. Gastroenterol. Hepatol.201530111591159510.1111/jgh.1300125967740
     [Google Scholar]
  13. PrattP.K.Jr DavidN. WeberH.C. LittleF.F. KourkoumpetisT. PattsG.J. WeinbergJ. FarrayeF.A. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy.Inflamm. Bowel Dis.201824238038610.1093/ibd/izx00129361083
     [Google Scholar]
  14. TunG.S.Z. RazaM. HaleM.F. LoboA.J. Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis.Ann. Gastroenterol.2019321818710.20524/aog.2018.031830598596
     [Google Scholar]
  15. NaharS. HokamaA. FujitaJ. Clinical significance of cytomegalovirus and other herpes virus infections in ulcerative colitis.Pol. Arch. Intern. Med.2019129962062610.20452/pamw.1483531111828
     [Google Scholar]
  16. SerreroM. Peyrin-BirouletL. GrimaudJ.C. IBD and HIV: “Dangerous Liaisons.Hepato-Gastro & Oncologie Digestive.2017241344110.1684/hpg.2016.1398
     [Google Scholar]
  17. AlzahraniJ. HussainT. SimarD. PalchaudhuriR. Abdel-MohsenM. CroweS.M. MbogoG.W. PalmerC.S. Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities.EBioMedicine20194652253110.1016/j.ebiom.2019.07.02731327693
     [Google Scholar]
  18. SchreinerP. MuellerN.J. FehrJ. MaillardM.H. BrandS. MichettiP. SchoepferA. RestelliniS. VulliemozM. VavrickaS.R. JuilleratP. RoglerG. BiedermannL. Varicella zoster virus in inflammatory bowel disease patients: What every gastroenterologist should know.J. Crohn’s Colitis2020jjaa13210.1093/ecco‑jcc/jjaa13232592587
     [Google Scholar]
  19. SohH. ChunJ. HanK. ParkS. ChoiG. KimJ. LeeJ. ImJ.P. KimJ.S. Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: A nationwide population-based study.Gut Liver201913333334110.5009/gnl1830430602222
     [Google Scholar]
  20. SokolH. LeducqV. AschardH. PhamH.P. JegouS. LandmanC. CohenD. LiguoriG. BourrierA. Nion-LarmurierI. CosnesJ. SeksikP. LangellaP. SkurnikD. RichardM.L. BeaugerieL. Fungal microbiota dysbiosis in IBD.Gut20176661039104810.1136/gutjnl‑2015‑31074626843508
     [Google Scholar]
  21. TinsleyA. NavabiS. WilliamsE.D. LiuG. KongL. CoatesM.D. ClarkeK. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease.Inflamm. Bowel Dis.201925236937610.1093/ibd/izy24330020478
     [Google Scholar]
  22. HosomiS. WatanabeK. NishidaY. YamagamiH. YukawaT. OtaniK. NagamiY. TanakaF. TairaK. KamataN. TanigawaT. ShibaM. WatanabeT. NagaharaH. MaedaK. FujiwaraY. Combined infection of human herpes viruses: A risk factor for subsequent colectomy in ulcerative colitis.Inflamm. Bowel Dis.20182461307131510.1093/ibd/izy00529668948
     [Google Scholar]
  23. StamatiadesG.A. IoannouP. PetrikkosG. TsioutisC. Fungal infections in patients with inflammatory bowel disease: A systematic review.Mycoses201861636637610.1111/myc.1275329453860
     [Google Scholar]
  24. StensvoldC.R. van der GiezenM. Associations between gut microbiota and common luminal intestinal parasites.Trends Parasitol.201834536937710.1016/j.pt.2018.02.00429567298
     [Google Scholar]
  25. LiuW. TangS. ZhaoQ. ZhangW. LiK. YaoW. GaoX. The α-D-glucan from marine fungus Phoma herbarum YS4108 ameliorated mice colitis by repairing mucosal barrier and maintaining intestinal homeostasis.Int. J. Biol. Macromol.20201491180118810.1016/j.ijbiomac.2020.01.30332014479
     [Google Scholar]
  26. ByunJ.M. LeeC.K. RheeS.Y. KimH.J. ImJ.P. ParkD.I. EunC.S. JungS.A. ShinJ.E. LeeK.M. CheonJ.H. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.Scand. J. Gastroenterol.201550331232010.3109/00365521.2014.100096025581784
     [Google Scholar]
  27. KimE.S. SongG.A. ChoK.B. ParkK.S. KimK.O. JangB.I. KimE.Y. JeonS.W. LeeH.S. YangC.H. LeeY.K. LeeD.W. KimS.K. KimT.O. LeeJ. KimH.W. JeeS.R. ParkS.J. KimH.J. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.World J. Gastroenterol.201521113308331610.3748/wjg.v21.i11.330825805938
     [Google Scholar]
  28. AgarwalA. KediaS. JainS. GuptaV. BopannaS. YadavD.P. GoyalS. MouliV.P. DhingraR. MakhariaG. AhujaV. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India.Intest. Res.201816458859810.5217/ir.2018.0002330301331
     [Google Scholar]
  29. DrevnoD. HickokS. AliS. P016 improving tuberculosis re screening in inflammatory bowel disease patients receiving biologic therapy: a single center quality improvement initiative.Inflamm. Bowel Dis.202026Suppl. 1S52S5310.1093/ibd/zaa010.132
     [Google Scholar]
  30. SatoR. NagaiH. MatsuiH. YamaneA. KawashimaM. HigaK. NakamuraS. OhshimaN. TamuraA. HebisawaA. Ten cases of intestinal tuberculosis which were initially misdiagnosed as inflammatory bowel disease.Intern. Med.201958142003200810.2169/internalmedicine.2361‑1830918188
     [Google Scholar]
  31. QasemA. NaserA.E. NaserS.A. The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn’s disease.Expert Rev. Anti Infect. Ther.201715763764310.1080/14787210.2017.132827628481651
     [Google Scholar]
  32. SinganayagamA. GlanvilleN. CuthbertsonL. BartlettN.W. FinneyL.J. TurekE. BakhsolianiE. CalderazzoM.A. Trujillo-TorralboM.B. FootittJ. JamesP.L. FenwickP. KempS.V. ClarkeT.B. WedzichaJ.A. EdwardsM.R. MoffattM. CooksonW.O. MalliaP. JohnstonS.L. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease.Sci. Transl. Med.201911507eaav387910.1126/scitranslmed.aav387931462509
     [Google Scholar]
  33. AbreuC. Rocha-PereiraN. SarmentoA. MagroF. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review.World J. Gastroenterol.201521216491649810.3748/wjg.v21.i21.649126074688
     [Google Scholar]
  34. MagroF. GionchettiP. EliakimR. ArdizzoneS. ArmuzziA. Barreiro-de AcostaM. BurischJ. GecseK.B. HartA.L. HindryckxP. LangnerC. LimdiJ.K. PellinoG. ZagórowiczE. RaineT. HarbordM. RiederF. European Crohn’s and Colitis Organisation [ECCO] (2017). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.J. Crohn’s Colitis201711664967010.1093/ecco‑jcc/jjx00828158501
     [Google Scholar]
  35. SchultzB.M. PaduroC.A. SalazarG.A. Salazar-EchegaraiF.J. SebastiánV.P. RiedelC.A. KalergisA.M. Alvarez-LobosM. BuenoS.M. A potential role of salmonella infection in the onset of inflammatory bowel diseases.Front. Immunol.2017819110.3389/fimmu.2017.0019128293241
     [Google Scholar]
  36. LiuJ. GuZ. SongF. ZhangH. ZhaoJ. ChenW. Lactobacillus plantarum ZS2058 and Lactobacillus rhamnosus GG use different mechanisms to prevent salmonella infection in vivo.Front. Microbiol.20191029910.3389/fmicb.2019.0029930842764
     [Google Scholar]
  37. Mirsepasi-LauridsenH.C. VallanceB.A. KrogfeltK.A. PetersenA.M. Escherichia coli pathobionts associated with inflammatory bowel disease.Clin. Microbiol. Rev.2019322e00060e1810.1128/CMR.00060‑1830700431
     [Google Scholar]
  38. ChennouF. HabouriL. JantchouP. A262 clostridium difficile infection in children with inflammatory bowel disease: A single center cross-sectional study.J. Can. Assoc. Gastroenterol.20192Suppl. 251551610.1093/jcag/gwz006.261
     [Google Scholar]
  39. HirtenR.P. GrinspanA. FuS.C. LuoY. Suarez-FarinasM. RowlandJ. ContijochE.J. MognoI. YangN. LuongT. LabriasP.R. PeterI. ChoJ.H. SandsB.E. ColombelJ.F. FaithJ.J. ClementeJ.C. Microbial engraftment and efficacy of fecal microbiota transplant for clostridium difficile in patients with and without inflammatory bowel disease.Inflamm. Bowel Dis.201925696997910.1093/ibd/izy39830852592
     [Google Scholar]
  40. AnanthakrishnanA.N. DonaldsonT. LaschK. YajnikV. Management of inflammatory bowel disease in the elderly patient: Challenges and opportunities.Inflamm. Bowel Dis.201723688289310.1097/MIB.000000000000109928375885
     [Google Scholar]
  41. D’HaensG.R. SlatkinN. IsraelR. HeimansonZ. P097 favorable safety profile for amiselimod, a selective s1p receptor modulator, in Crohn’s disease.Inflamm. Bowel Dis.202026Suppl. 1S1S210.1093/ibd/zaa010.002
     [Google Scholar]
  42. FerranteM. FeaganB.G. PanésJ. BaertF. LouisE. DewitO. KaserA. DuanW.R. GustafsonD. LiaoX. WallaceK. KalabicJ. D’HaensG.R. OP27 Long-term safety and efficacy of risankizumab treatment in patients with crohn’s disease: final results from the phase 2 open-label extension study.J. Crohn’s Colitis202014Suppl. 1S024S02510.1093/ecco‑jcc/jjz203.026
     [Google Scholar]
  43. ZhaoM. LördalM. LangholzE. KnudsenT. VoutilainenM. HøivikM.L. MoumB. SaeboB. HaikoP. MalmgrenC. CoskunM. MelbergH.O. BurischJ. Høivik, Ml. et al. OP35 treatment outcomes of inflammatory bowel disease in the biological era-a nationwide retrospective cohort study in three nordic countries: Results from the trinordic study.J. Crohn’s Colitis202014Suppl. 1S036S03710.1093/ecco‑jcc/jjz203.034
     [Google Scholar]
  44. NaldiniG. SturialeA. FabianiB. GianiI. MenconiC. Micro-fragmented adipose tissue injection for the treatment of complex anal fistula: a pilot study accessing safety and feasibility.Tech. Coloproctol.201822210711310.1007/s10151‑018‑1755‑829453515
     [Google Scholar]
  45. PuglieseD. PriviteraG. ArmuzziA. P477 Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of inflammatory bowel disease: The elderly cohort.J. Crohn’s Colitis202014Suppl. 1S419S42210.1093/ecco‑jcc/jjz203.606
     [Google Scholar]
  46. GongS.S. FanY.H. HanQ.Q. LvB. XuY. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.World J. Gastroenterol.201925182240225010.3748/wjg.v25.i18.224031143074
     [Google Scholar]
  47. TretinaK. ParkE.S. MaminskaA. MacMickingJ.D. Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease.J. Exp. Med.2019216348250010.1084/jem.2018203130755454
     [Google Scholar]
  48. WangX. BootsmaH. KroeseF. DijkstraG. PringleS. Senescent stem and transient amplifying cells in crohn’s disease intestine.Inflamm. Bowel Dis.2020262e8e910.1093/ibd/izz29531769481
     [Google Scholar]
  49. MalhamM. LiljeB. HouenG. WintherK. AndersenP.S. JakobsenC. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease.Scand. J. Gastroenterol.201954896997510.1080/00365521.2019.164436831329473
     [Google Scholar]
  50. RubinD.T. DubinskyM.C. PanésJ. WuD.C. LawendyN. GuoX. LaiC. KwokK. SuC. SaleseL. DOP75 efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study.J. Crohn’s Colitis202014Suppl. 1S112S11310.1093/ecco‑jcc/jjz203.114
     [Google Scholar]
  51. PerryC. KapurN. BarrettT.A. Neeraj, Kapur PhD.; Terrence A, Barrett, MD. DPP-4 as a novel biomarker for inflammatory bowel disease: Is it ready for clinical use?Inflamm. Bowel Dis.202026111720172110.1093/ibd/izz32031913471
     [Google Scholar]
  52. deBruynJ.C.C. SoonI.S. FonsecaK. FengS. PurtzkiM. GoedhartC. KuhnS. VanderkooiO.G. WrobelI. Serologic status of routine childhood vaccines, cytomegalovirus, and Epstein-Barr virus in children with inflammatory bowel disease.Inflamm. Bowel Dis.20192571218122610.1093/ibd/izy36630551205
     [Google Scholar]
  53. NeurathM.F. COVID-19 and immunomodulation in IBD.Gut20206971335134210.1136/gutjnl‑2020‑32126932303609
     [Google Scholar]
  54. Al-AniA.H. PrenticeR.E. RentschC.A. JohnsonD. ArdalanZ. HeerasingN. GargM. CampbellS. SasadeuszJ. MacraeF.A. NgS.C. RubinD.T. ChristensenB. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.Aliment. Pharmacol. Ther.2020521547210.1111/apt.1577932348598
     [Google Scholar]
/content/journals/ijghd/10.2174/2666290601666220124111511
Loading
The Risk of Opportunistic Infections in Patients with Inflammatory Bowel Disease
Int J Gastroenterol Hepatol Dis 1, e240122200473 (2022); https://doi.org/10.2174/2666290601666220124111511
/content/journals/ijghd/10.2174/2666290601666220124111511
/content/journals/ijghd/10.2174/2666290601666220124111511
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Crohn's disease; Inflammatory bowel disease; intestinal microbiota; opportunistic infections; therapeutic strategy; ulcerative colitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test